The Effect of PC945 on Aspergillus Fumigatus Lung Infection in Patients With Cystic Fibrosis

An Open-label Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Inhaled PC945 in Adult Cystic Fibrosis (CF) Patients With Persistent Pulmonary Aspergillus Fumigatus Infection

This study tests the effects of an experimental drug PC945 in people with cystic fibrosis whose lungs are infected by the fungus Aspergillus fumigatus.

PC945 may be useful in treating patients infected with Aspergillus fumigatus as, unlike the usual treatments, it is inhaled into the lung and has been designed to stay there and treat the infection. Participants will continue to be treated with their usual cystic fibrosis treatment and will also receive PC945. The amount of fungus in the patients' phlegm will be measured over the course of the study. The study will take place at multiple sites in UK and will include approximately 18 participants. The maximum study duration will be about 16 weeks.

Study Overview

• Status: Terminated
• Conditions: Cystic Fibrosis; Aspergillosis
• Intervention / Treatment: Drug: PC945

• Study Type: Interventional
• Enrollment (Actual): 4
• Phase: Phase 2

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom, SW3 6NP
    • Royal Brompton Hospital
  • Manchester, United Kingdom, M23 9LT
    • Northwest Lung Research Centre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Subject must be male or female, aged 18 years inclusive or older (at the time of consent).
2. Subject must be willing and able to adhere to the restrictions and prohibitions required by this protocol.
3. Each subject must sign an informed consent form (ICF) indicating that he or she understands the purpose and requirements of the study and that they are willing to participate.
4. A confirmed diagnosis of CF by standard criteria.
5. Subject is able to produce sputum.
6. A history of persistently positive A. fumigatus sputum cultures from at least 2 sputum samples in the last year, the most recent of which must have been within the last 6 months.
7. Subject must have a positive sputum fungal culture at screening with one or more colonies of A. fumigatus detected using a modified standard approach.

Exclusion Criteria:

1. Any other disease or condition, which in the Investigator's medical opinion would preclude the subject's participation in a clinical trial.
2. Is taking inhaled amphotericin B or has taken it within 7 weeks of Day 1.
3. Is taking systemic steroid treatment or has taken it within 4 weeks of Day 1. Subjects considered to be stable on a systemic steroid dose of <15 mg for at least a month will not be excluded.
4. Is taking systemic antifungal treatment (intravenous, oral or inhaled) or has received antifungal therapy (intravenous, oral or inhaled) within 6 weeks of Day 1.
5. If female, the subject is pregnant (e.g., has a positive serum β human chorionic gonadotropin (β-hCG) at screening or a positive urinary pregnancy test pre-dose on Day 1), lactating or breast feeding.
6. Any respiratory exacerbation within 2 weeks of the start of the study.
7. Any upper respiratory tract infection or signs or symptoms thereof within 2 weeks prior to dosing.
8. Positive culture for Mycobacterium abscessus within 12 months before screening or between screening and baseline, or currently receiving treatment for Mycobacterium abscessus.
9. Has chronic, active hepatitis or a positive hepatitis B surface antigen or positive hepatitis C antibody result at screening.
10. Is taking antiretroviral protease inhibitor therapy.
11. Allergy to any of the active or inactive ingredients in the study medication.
12. History of drug (or other) allergy or intolerance that, in the opinion of the Investigator or Pulmocide Medical Monitor, would contraindicate their participation.
13. Clinically significant haemoptysis (>200 mL per episode) within 90 days before screening.
14. Subject is mentally or legally incapacitated. 19 July 2018 CONFIDENTIAL Page 27 of 58 Pulmocide Ltd Clinical Protocol PC_ASP_003
15. Subject is employed or is a first-degree relative of anyone employed by Pulmocide, a participating clinical trial site, or any contract research organisation involved in the study.
16. Any other reason that the Investigator considers makes the subject unsuitable to participate.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: PC945; PC945 5mg once daily	Drug: PC945; PC945, nebulized

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events (AEs)		Baseline to Day 84
Proportion of participants who meet the markedly abnormal criteria for 12-lead ECG assessment at lease once post dose		Baseline to Day 84
Proportion of participants who meet the markedly abnormal criteria for safety laboratory assessment at lease once post dose		Baseline to Day 84
Proportion of participants who meet the markedly abnormal criteria for vital signs assessment at lease once post dose		Baseline to Day 84
Predicted post bronchodilator forced expiratory volume in 1 second (FEV1) values		Baseline to Day 84
Forced vital capacity (FVC) values		Baseline to Day 84
Peak expiratory flow rate values (PEFR)		Baseline to Day 84
Maximum expiratory flow values (MEF25-75)		Baseline to Day 84
Breathlessness visual analogue scale rating, change over time	Symptom severity rated from "Best ever" to "Worst possible"	Baseline to Day 84
Cough visual analogue scale rating, change over time	Symptom severity rated from "Best ever" to "Worst possible"	Baseline to Day 84
Area under the curve from time 0 to 2 h post-dose (AUC0-2)	Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable	Baseline to Day 84
Maximum plasma concentration	Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable	Baseline to Day 84
Concentration at the end of the dosage interval (Ctrough)	Derived pharmacokinetic parameters for PC945 and the potential circulating metabolite(s), if detectable	Baseline to Day 84

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in the number of sputum A. fumigatus colony forming units (CFU)		Baseline to Day 84
A. fumigatus status (presence or absence) in subjects with a baseline A. fumigatus-positive sputum culture		Day 1 to Day 84
Change in sputum A. fumigatus measured by quantitative polymerase chain reaction (qPCR)		Baseline to Day 84
Change in the serum concentration of A. fumigatus-specific immunoglobulins G (IgG)		Baseline to Day 84
Change in serum Total immunoglobulin E (IgE) levels		Baseline to Day 84
Change in serum Aspergillus-specific IgE levels		Baseline to Day 84
Correlation between A. fumigatus measured by qPCR and clinical response		Baseline to Day 84
Cystic Fibrosis Questionnaire - Revised (CFQ-R) score		Baseline to Day 84
Sputum consistency, including presence of blood	Categorical variable	Baseline to Day 84
Sputum colour	Categorical variable using standardised colour chart.	Baseline to Day 84

Collaborators and Investigators

• Sponsor: Pulmocide Ltd

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 3, 2019
• Primary Completion (ACTUAL): June 1, 2020
• Study Completion (ACTUAL): June 1, 2020

Study Registration Dates

• First Submitted: October 24, 2018
• First Submitted That Met QC Criteria: March 8, 2019
• First Posted (ACTUAL): March 12, 2019

Study Record Updates

• Last Update Posted (ACTUAL): July 16, 2021
• Last Update Submitted That Met QC Criteria: July 15, 2021
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Infections; Respiratory Tract Diseases; Lung Diseases; Infant, Newborn, Diseases; Genetic Diseases, Inborn; Bacterial Infections and Mycoses; Mycoses; Pancreatic Diseases; Fibrosis; Cystic Fibrosis; Aspergillosis
• Other Study ID Numbers: PC_ASP_003; 2018-000243-87 (EUDRACT_NUMBER)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No